3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
1
Neoplasms
1
Inflammation
1
Cognitive Dysfunction
1
Chemotherapy-Related Cognitive Impairment
1
Autoimmune Diseases
1
Interventions
Cognitive Training
2
Tobacco Use Cessation Devices
1
Sodium Chloride
1
Saline Solution
1
Palliative Care
1
Neuroprotective Agents
1
Mesna
1
Magnetic Resonance Spectroscopy
1
High-Intensity Interval Training
1
Functional Status
1
Electroacupuncture
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Ashwagandha
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Chemotherapy-Related Cognitive Impairment
×
Ashwagandha
×
Clear all
NCT04092647
2023-06-15
Ashwagandha for Cognitive Dysfunction
Sutter Health
Phase 2
Unknown
80 enrolled